{"id":3011,"date":"2024-01-17T09:46:00","date_gmt":"2024-01-17T09:46:00","guid":{"rendered":"https:\/\/discovery-park.co.uk\/?p=3011"},"modified":"2024-01-17T09:46:00","modified_gmt":"2024-01-17T09:46:00","slug":"discovery-park-ventures-invests-100k-in-new-tenant-vox-imaging-technology-to-advance-ophthalmic-imaging-for-preclinical-research","status":"publish","type":"post","link":"https:\/\/discovery-park.co.uk\/discovery-park-ventures-invests-100k-in-new-tenant-vox-imaging-technology-to-advance-ophthalmic-imaging-for-preclinical-research\/","title":{"rendered":"Discovery Park Ventures invests \u00a3100K in new tenant Vox Imaging Technology to advance ophthalmic imaging for preclinical research"},"content":{"rendered":"
Discovery Park Ventures (DPV)<\/a> announces an investment of \u00a3100K into Vox Imaging Technology Ltd. (VIT),<\/a> an ambitious ophthalmic technology company looking to transform eye imaging in preclinical research and improve drug discovery and development. Its compact and customisable instrument is believed to be the first scanning laser ophthalmoscope especially designed for laboratory use, able to produce high-quality data rapidly. Vox Imaging is the eighth investment from DPV\u2019s first fund.<\/p>\n Prevalence of diseases of the eye (such as age-related macular degeneration) and conditions in which the eye may be affected (such as diabetes) is increasing as the population ages. The resultant demand for new and better medicines for these conditions is helping to drive the global drug discovery market, expected to be worth over US $120 billion by 20301, and the need for new research instruments such as the VoxOne scanning laser ophthalmoscope.<\/p>\n Vox Imaging Technology was founded in 2021 by Peter West and Alan Robinson, who have extensive experience in developing innovative ophthalmic imaging systems from roles in industry and academia.<\/p>\n Discovery Park Ventures (DPV) recognised the VIT team\u2019s expertise in this high potential market and the advantages its technology offers over existing products.<\/p>\n The investment will enable the company to move into new premises at Discovery Park and will facilitate the completion of a working prototype and proof of concept testing prior to launch in 2025. The majority of customers are expected to be pharmaceutical and biotech companies or contract research organisations. Following the investment, DPV Director Dr Martino Picardo joins the company as Interim Chairman while fellow DPV Director Emma Palmer Foster joins Vox Imaging as Investor Director.<\/p>\n Peter West, Chief Technology Officer and Founder, Vox Imaging Technology, said: \u201cWe\u2019re gratified that Discovery Park Ventures recognised the potential impact of accurate ophthalmic imaging in early-stage research. Not only will their investment help to drive the development of our technology, but Discovery Park also offers the ideal location for us to grow the business with high-specification facilities, access to a wide network of potential partners and advisors, and a strong academic research community on our doorstep.\u201d<\/p>\n